|

Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

RECRUITINGN/ASponsored by Imperial College London
Actively Recruiting
PhaseN/A
SponsorImperial College London
Started2021-04-01
Est. completion2027-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04432025

Summary

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* eligible for bariatric surgery according to NICE guidelines (GC 189)
* Type 2 diabetes mellitus
* BMI \>30kg/m2

Exclusion Criteria:

* Recent hospitalisation in the past 30 days
* Recurrent hypoglycaemic episodes
* Recurrent hypotensive episodes
* Contraindications to bariatric surgery
* Previous bariatric surgery
* Current pregnancy
* Breastfeeding

Conditions3

DiabetesObesityType 2 Diabetes

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.